Skip to content

The Impact of rTMS and iTBS on cortical reactivity and EEG in aMCI patients

The Impact of rTMS and iTBS on cortical reactivity and EEG in aMCI patients

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900028180
Enrollment
Unknown
Registered
2019-12-14
Start date
2020-01-01
Completion date
Unknown
Last updated
2019-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

amnestic type mild cognitive impairment, aMCI

Interventions

rTMS Group:rTMS Stimulate
iTBS Group:iTBS Stimulate

Sponsors

The People's Hospital of Bao'an Shenzhen
Lead Sponsor

Eligibility

Sex/Gender
All
Age
55 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. aged 55–75 years old; 2. memory complaint, provided by the patient or family; 3. memory impairment for age; 4. right-handed; 5. Montreal Cognitive Assessment (MoCA) score <=26; 6. Clinical Dementia Rating Scale (CDR) of 0.5 points, or total decline scale (GDS) of 2 to 3; 7. Normal daily living ability.

Exclusion criteria

Exclusion criteria: 1. other diseases that cause cognitive decline(e.g., stroke, vascular, Parkinson's disease, traumatic, medical); 2. they had a Hachinski Ischaemic score of >4 or/and Hamilton Depression Scale (HAMD) >8 points; 3. People with claustrophobia and disorders such as deafness, language impairment and blindness could not perform MRI and cognitive function test; 4. had contraindications for TMS, such as implanting metal objects in the body, installation of electronic devices, pacemakers.

Design outcomes

Primary

MeasureTime frame
TMS-EEG;P300;

Secondary

MeasureTime frame
MoCA;EEG;

Countries

China

Contacts

Public ContactZHU Fen

The People's Hospital of Bao'an Shenzhen

453945262@qq.com+86 13662657971

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 17, 2026